Mylan asks US court to clear Wegovy generic from Novo patent claims

By Reuters News

By Blake Brittain

Sept 25 (Reuters) - Generic drugmaker Viatris VTRS.O has sued Danish pharmaceutical giant Novo Nordisk NOVOb.CO in Delaware federal court, seeking a ruling that its proposed generic of Novo's blockbuster GLP-1 drug Wegovy would not violate Novo's patent rights.

  • Viatris' Mylan Pharmaceuticals asked the court in a filing made public on Thursday to find that its generic would not infringe Novo's patent covering a method of administering single-dose Wegovy pens for weight loss.

  • A Novo spokesperson declined to comment on the lawsuit on Friday, citing pending litigation.

  • Spokespeople for Viatris did not immediately respond to a request for comment on the lawsuit.

  • Novo earned nearly $31 billion from its blockbuster semaglutide-based weight loss drugs Wegovy and Ozempic last year, according to a company report.

  • Generic versions of Wegovy and Ozempic cannot enter the US market until 2032, when Novo patents covering the drugs' active ingredient semaglutide expire.

  • Novo has settled other patent lawsuits over proposed Wegovy and Ozempic generics against Mylan and other drugmakers.

The case is Mylan Pharmaceuticals Inc v. Novo Nordisk Inc, US District Court for the District of Delaware, No. 1:26-cv-01192.

For Mylan: Shannon Bloodworth of Ashurst Perkins Coie

For Novo: attorney information not yet available

Read more:

Novo Nordisk settles US patent fight with Viatris over Ozempic

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.